The CD70-targeting allogeneic CAR T-cell therapy, ALLO-316, demonstrated encouraging response rates and disease control rates in patients with metastatic clear cell renal cell carcinoma, according to results of a phase I trial led by researchers at MD Anderson Cancer Center and presented at the American Association for Cancer Research annual meeting.
I joined Translational Genomics Research Institute, part of City of Hope, late last year to launch the Center for Accelerated Nanotherapeutics.
